# Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APB-R3

> **NCT05715736** · PHASE1 · COMPLETED · sponsor: **Syneos Health** · enrollment: 31 (actual)

## Conditions studied

- Still's Disease, Adult-Onset

## Interventions

- **DRUG:** APB-R3
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05715736
- **Lead sponsor:** Syneos Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-08
- **Primary completion:** 2023-12-19
- **Final completion:** 2023-12-19
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2024-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05715736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05715736, "Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APB-R3". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05715736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*